Results 81 to 90 of about 16,400 (167)

Transition Into Clinical Routine and Survival Outcomes of BCL2‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry

European Journal of Haematology, Volume 117, Issue 2, Page 351-357, August 2026.
ABSTRACT Within a dataset of the German CLL Study Group (GCLLSG) registry, 274 patients were allocated to a cohort with venetoclax and 888 to a cohort with BTKi (79 acalabrutinib, 809 ibrutinib), each as first administered targeted substance class within the documented treatment sequence.
Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht, Hartmut Linde, Thomas Illmer, Steffen Dörfel, Jörg Lipke, Ali Aldaoud, Rudolf Schlag, Jolanta Dengler, Othman Al‐Sawaf, Petra Langerbeins, Paula Cramer, Michael Hallek, Barbara Eichhorst, Kirsten Fischer, Anna Fink   +16 more
wiley   +1 more source

First‐Line Treatment of IGHV‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens

European Journal of Haematology, Volume 117, Issue 2, Page 375-383, August 2026.
ABSTRACT Immunoglobulin heavy chain variable region‐unmutated (IGHV‐U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta‐analysis of ...
Santino Caserta, Enrica Antonia Martino, Danilo Lofaro, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Fortunato Morabito, Valter Gattei, Massimo Gentile   +13 more
wiley   +1 more source

From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management

European Journal of Haematology, Volume 117, Issue 2, Page 305-319, August 2026.
ABSTRACT The integration of measurable residual disease (MRD) into the management of chronic lymphocytic leukemia (CLL) has emerged as a major advance in risk stratification and trial design, particularly in the context of time‐limited, targeted regimens.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Mamdouh Skafi, Valter Gattei, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR‐T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT The tumour microenvironment (TME) of relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) patients is associated with resistance of DLBCL cells to CD19 CAR‐T cells. How to improve TME in DLBCL and improve the efficacy of CAR‐T cell therapy remains to be further explored.
Yao Qi, Xuemei Fan, Jia Wang, Xin Li, Juan Mu, Rui Cui, Qi Deng   +6 more
wiley   +1 more source

Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Frontiers in Hematology
BackgroundMantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses ...
Catarina Fernandes, Rita Costa e Sousa, Pedro Santos, Cátia Almeida, Adriana Roque, Ana Luísa Pinto, Joaquim Monteiro, Anabela Neves, Maria João Ramos, Rita Coutinho, Rita Coutinho, Rita Coutinho, Filipa Mousinho, Mariana Leal Fernandes, Margarida Badior, Cristina João, Cristina João, Sónia Leocádio, Ana Luísa Tomé, Margarida Carrolo, Sara Dias, Maria Gomes da Silva, João Paulo Fernandes   +22 more
doaj   +1 more source

Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route

Therapeutic Advances in Hematology
Background: Ibrutinib is the only Bruton tyrosine kinase inhibitor (BTKi) with once-daily oral capsule, tablet, and oral suspension formulations approved in the United States across indications of chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Jonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, Michelle Pacia, Heena Mavani, Harisha Atluri, Thomas J. Huemann, Jessica Shelly, Yemin Liu, Shayna Sarosiek   +9 more
doaj   +1 more source

Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes

Research
Background: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF).
Yukun Li, Xinmeng Liu, Rong Lin, Xiaodong Peng, Xuesi Wang, Fanchao Meng, Shuqi Jin, Wenhe Lv, Xiaoying Liu, Zhuohang Du, Songnan Wen, Rong Bai, Yanfei Ruan, Hao Zhou, Rongjun Zou, Ribo Tang, Nian Liu   +16 more
doaj   +1 more source

First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs. [PDF]

Clinicoecon Outcomes Res
Perrone V, Innao V, Mazzoni S, Cappuccilli M, Andretta M, Bartolini F, Chinellato A, Dell'Orco S, Ferrante F, Lombardi R, Pagliaro R, Ubertazzo L, Valpondi P, Degli Esposti L.   +13 more
europepmc   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma. [PDF]

Hemasphere
Belada D, Gardner FP, de Oliveira AC, Sancho JM, Lomaia E, Wright D, Turgut M, Martynova E, Lázár Z, Anz B, Wang MC, Legiec W, Opat S, Pailden J, Peltier HM, Marturano E, Dean JP, Flinn IW.   +17 more
europepmc   +1 more source

Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States. [PDF]

Front Public Health
He J, Liu X, Yang Q.
europepmc   +1 more source